Am J Manag Care. 2000 May;6(9 Suppl):S480-3.
Acid-related diseases, such as gastroesophageal reflux disease (GERD), have a significant impact on healthcare costs. As a result, healthcare providers must devise ways to limit expenditures while providing high-quality patient care. Although the goals of therapy are the same in both traditional fee-for-service and managed care environments, optimal cost-containment strategies depend heavily on the specifics of payment and risk arrangements involved. Cost-saving strategies involving drug therapy are often based on the assumption that treatments with lower acquisition costs are the most cost effective. In the case of GERD treatment, the respective efficacies of acid-suppression therapies should also be considered. In addition, efficacy should be a major consideration in therapy choice because GERD recurrence and complications as a result of ineffective therapies can negatively affect patients' quality of life and increase the overall cost of healthcare. The advantages and limitations of endoscopy as a prognostic tool should also be considered in an assessment of cost-effective GERD treatment.
酸相关性疾病，如胃食管反流病（GERD），对医疗成本有重大影响。因此，医疗服务提供者必须想出办法在提供高质量患者护理的同时限制支出。尽管在传统的按服务收费和管理式医疗环境中治疗目标是相同的，但最佳的成本控制策略在很大程度上取决于所涉及的支付和风险安排的具体情况。涉及药物治疗的成本节约策略通常基于这样一种假设，即采购成本较低的治疗方法是最具成本效益的。在GERD治疗中，还应考虑抑酸疗法的各自疗效。此外，疗效应是治疗选择的主要考虑因素，因为无效治疗导致的GERD复发和并发症会对患者的生活质量产生负面影响，并增加医疗保健的总体成本。在评估GERD的成本效益治疗时，也应考虑内镜检查作为一种预后工具的优点和局限性。
